Latham & Watkins LLP represented the underwriters in the offering of Athenex, assisted by Harter Secrest & Emery LLP.
Athenex, Inc. announced the pricing of a public offering of 10,000,000 shares of its common stock at a public offering price of US$11.00 per share. The gross proceeds to Athenex from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be US$110 million. In addition, Athenex has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
SVB Leerink LLC, RBC Capital Markets, LLC, Evercore Group L.L.C., and Oppenheimer & Co. Inc. acted as underwriters for the offering.
Athenex, Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.
Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili (Picture) and Bay Area partner Brian Cuneo, with Bay Area associate Phillip Stoup, and New York associates Milo LeDoux and MacLane Taggart.
The HSE Securities and Capital Markets team for the transaction included Alexander R. McClean, Sarah H. Brennan, C. Christopher Murillo, and Ryan A. Whelpley.
Involved fees earner: Sarah Brennan – Harter Secrest & Emery; Alexander McClean – Harter Secrest & Emery; Christopher Murillo – Harter Secrest & Emery; Ryan Whelpley – Harter Secrest & Emery; Nathan Ajiashvili – Latham & Watkins; Brian Cuneo – Latham & Watkins; Milo LeDoux – Latham & Watkins; Phillip Stoup – Latham & Watkins; MacLane Taggart – Latham & Watkins;